



24 July 2023

AIM: RENE

**ReNeuron Group plc  
("ReNeuron" or the "Company")**

**Notice of Annual General Meeting**

**ReNeuron Group plc (AIM: RENE)**, a UK-based leader in stem cell derived exosome technologies, announces that the Notice of Annual General Meeting ("AGM") and Form of Proxy have today been posted to shareholders and will shortly be available on the investors section of the Company's website [here](#).

The AGM will be held at the offices of Covington & Burling LLP, Level 54, 22 Bishopsgate, London EC2N 4BQ on 22 August 2023 at 9.30 a.m.

The Board welcomes the opportunity to invite shareholders to attend the AGM in person. Persons intending to attend and vote at the meeting in person will need a QR code to access the meeting venue. Such QR code will need to be displayed on a smartphone or similar device. A QR code will be able to be obtained in advance by emailing [externalproxyqueries@computershare.co.uk](mailto:externalproxyqueries@computershare.co.uk) with your full name and email address. Please note that this email address should be used for this purpose only, and the Registrar will not be able to respond to any other form of communication or enquiry sent to this email address. Persons who have not obtained a QR code in advance will be able to obtain one at the meeting venue.

If shareholders are unable to attend the meeting in person, then they are encouraged to submit their votes by proxy by appointing the Chairman of the AGM as their proxy, so that their votes can be taken into account.

Shareholders are also encouraged to submit any questions for the Chairman to [info@reneuron.com](mailto:info@reneuron.com) at least 48 hours prior to the Meeting. Shareholders that are able to attend the AGM in person will also have an opportunity to ask questions at the Meeting. Where appropriate, questions and answers will be collated and later published on the Company's website at [www.reneuron.com](http://www.reneuron.com).

The results of the proposed resolutions will be published on the Company website and announced via RNS as soon as practicable after the conclusion of the AGM.

**ENDS**

**Enquiries:**

**ReNeuron**

Iain Ross, Executive Chairman  
John Hawkins, Chief Financial Officer

[www.reneuron.com/investors](http://www.reneuron.com/investors)

Via Walbrook PR

**Allenby Capital Limited (Nominated Adviser and Broker)**

James Reeve/George Payne/Dan Dearden-Williams  
(Corporate Finance)  
Stefano Aquilino (Sales & Corporate Broking)

+44 (0)20 3328 5656

**Walbrook PR (Media & Investor Relations)**

Paul McManus / Alice Woodings

+44 (0)20 7933 8780 or [reneuron@walbrookpr.com](mailto:reneuron@walbrookpr.com)

+44 (0)7980 541 893 / +44 (0)7407 804 654

**About ReNeuron**

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit [www.reneuron.com](http://www.reneuron.com)